Tag Archives: Jaguar Gene Therapy

Zealand Restructures Business to Focus on R&D and Cuts 90% of US Workforce; Samsung and JDRF T1DM Invest in Jaguar Gene Therapy

Two cardiometabolic-related news items have been observed: Zealand announced a company restructuring comprised of a shift back toward an R&D organization, a CEO transition, and a 90% US workforce reduction (listen to call investor call here); and Jaguar Gene Therapy announced Samsung Ventures and the JDRF T1D Fund have invested in the company. Below, FENIX provides highlights and insights for the respective new items. 

This content is for Read Less members only.
Register
Already a member? Log in here

Sigilon Announces Strategic Reprioritization; Jaguar Gene Therapy Includes T1DM in Initial Pipeline Program

Two cardiometabolic-related news items have been observed: Sigilon Therapeutics announced plans for a strategic reprioritization to focus on its MPS-1 and beta cell therapy for T1DM, including a 38% workforce reduction; and Jaguar Gene Therapy announced target genes for its initial pipeline programs in T1DM, autism, and T1 Galactosemia. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here